Olema Pharmaceuticals Inc (OLMA) Institutional Investor Snapshot (185 Funds, Q2 2026)

OLMA ranks #3212 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

OLMA is a top-conviction position for Bain Capital Life Sciences Investors, LLC — at 5.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in OLMA belongs to FMR LLC, but the position matters far more to Bain Capital Life Sciences Investors, LLC, who has 5.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Versant Capital Management, Inc has trimmed its OLMA position for two straight quarters, cutting it by $10.9K while still holding $9.7K.

OLMA is down 1.6% today, but institutions show net buying of $101.3M this quarter — a divergence between today's price move and the underlying institutional flow.

OLMA reported a net loss of $162.5M in its latest fiscal year.

• Not yet profitable — net loss of $162.5M in the latest fiscal year
• Net income declined year over year, from -$129.5M to -$162.5M
• Operating cash flow was negative, using $146.7M in cash
• Current ratio of 9.95x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.11x equity — within a conventional range